HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The effects of 1,4-dimethylpyridine in metastatic prostate cancer in mice.

AbstractBACKGROUND:
We previously showed that 1-methylnicotinamide (1-MNA) and its analog 1,4-dimethylpyridine (1,4-DMP) could inhibit the formation of lung metastases and enhance the efficacy of cyclophosphamide-based chemotherapy in the model of spontaneously metastasizing 4T1 mouse mammary gland tumors. In the present study, we aimed to investigate whether the previously observed activity of pyridine compounds pertains also to the prevention and the treatment of metastatic prostate tumors, in a combined chemotherapy with docetaxel.
METHODS:
Cancer-preventing activity of 1,4-DMP was studied in the model of prostate tumors spontaneously arising in C57BL/6-Tg (TRAMP)8247Ng/J (TRAMP) mice. The efficacy of the combined chemotherapy, comprising simultaneous use of 1,4-DMP and docetaxel, was evaluated in the orthotopic mouse model of human PC-3M-luc2 prostate cancer. The toxicity of the applied treatment was also determined.
RESULTS:
The development of prostate tumors in TRAMP mice remained unaffected after administration of 1,4-DMP. Similarly, no effect of 1,4-DMP was found on the growth of orthotopically transplanted PC-3M-luc2 tumors. However, when 1,4-DMP was administered along with docetaxel, it enhanced the anticancer activity of the chemotherapy. As a result, in PC-3M-luc2-bearing mice statistically significant inhibition of the tumor growth and lower metastases incidence were observed. The decreased metastatic yield is probably related to the diminished platelet activity observed in mice treated with combined therapeutic regimen. Finally, the combined treatment exhibited lowered side effects accompanying docetaxel administration.
CONCLUSIONS:
Results presented herein confirm previously published data on the anticancer activity of pyridine compounds and demonstrate that 1,4-DMP may be beneficially implemented into chemotherapy utilizing various cytotoxic agents, directed against multiple metastatic tumor types.
AuthorsAgnieszka Denslow, Marta Switalska, Marcin Nowak, Magdalena Maciejewska, Stefan Chlopicki, Andrzej Marcinek, Jerzy Gebicki, Joanna Wietrzyk
JournalBMC cancer (BMC Cancer) Vol. 17 Issue 1 Pg. 177 (03 07 2017) ISSN: 1471-2407 [Electronic] England
PMID28270133 (Publication Type: Journal Article)
Chemical References
  • Pyridines
  • Taxoids
  • Docetaxel
  • Niacinamide
  • Cyclophosphamide
  • pyridine
  • N(1)-methylnicotinamide
Topics
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
  • Cyclophosphamide (administration & dosage)
  • Disease Models, Animal
  • Docetaxel
  • Humans
  • Male
  • Mice
  • Neoplasm Metastasis
  • Niacinamide (administration & dosage, analogs & derivatives)
  • Prostatic Neoplasms (drug therapy, pathology)
  • Pyridines (administration & dosage)
  • Taxoids (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: